Literature DB >> 2564677

CD4+ lymphocyte function with early human immunodeficiency virus infection.

R J Gurley1, K Ikeuchi, R A Byrn, K Anderson, J E Groopman.   

Abstract

The pathogenesis of cellular immune deficiency following human immunodeficiency virus (HIV) infection could result from quantitative and/or qualitative dysfunction of the CD4+ lymphocyte population. To better characterize the T-cell response to soluble antigen with HIV infection, we have isolated peripheral blood lymphocytes and purified populations of CD4+ lymphocytes from healthy HIV antibody-positive subjects, patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC), and healthy HIV antibody-negative controls. T-lymphocyte function was determined by proliferative response to lectin (phytohemagglutinin), phorbol 12-myristate 13-acetate (PMA), calcium ionophore, purified recombinant HIV envelope gp120, tetanus toxoid antigen, and tetanus toxoid antigen in the presence of recombinant gp120 or purified recombinant soluble CD4. PBLs and CD4+ lymphocytes from asymptomatic HIV-infected subjects responded equally well to lectin, PMA, and/or calcium ionophore and to tetanus toxoid as cells from uninfected control subjects. The cells that proliferated in response to a soluble antigenic stimulus did not respond to gp120. Cells from subjects with ARC had a selective antigen recognition defect independent of the number of CD4+ lymphocytes. Recombinant gp120 inhibited CD4+ lymphocyte proliferation to antigenic stimulus by 30-40%. Recombinant soluble CD4, a proposed therapeutic for HIV, had no effect on T-cell response to antigen. A selective antigen recognition response was not compromised early in HIV infection but was compromised in subjects with ARC. Inhibition of proliferation to tetanus toxoid by gp120 suggests that HIV may affect major histocompatibility complex II restricted antigen recognition independent of CD4+ cell loss.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564677      PMCID: PMC286832          DOI: 10.1073/pnas.86.6.1993

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors:  C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

Review 3.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

4.  The regulation of intracellular signals during lymphocyte activation.

Authors:  J B Imboden
Journal:  Immunol Today       Date:  1988-01

5.  "Panning" for lymphocytes: a method for cell selection.

Authors:  L J Wysocki; V L Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

Review 6.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

7.  Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen.

Authors:  D Gay; P Maddon; R Sekaly; M A Talle; M Godfrey; E Long; G Goldstein; L Chess; R Axel; J Kappler
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

8.  A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).

Authors:  G M Shearer; D C Bernstein; K S Tung; C S Via; R Redfield; S Z Salahuddin; R C Gallo
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

9.  HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor.

Authors:  G P Linette; R J Hartzman; J A Ledbetter; C H June
Journal:  Science       Date:  1988-07-29       Impact factor: 47.728

10.  Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man.

Authors:  E G Engleman; C J Benike; E Glickman; R L Evans
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1.

Authors:  C Terai; R S Kornbluth; C D Pauza; D D Richman; D A Carson
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

3.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

4.  Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency.

Authors:  S L Waldrop; C J Pitcher; D M Peterson; V C Maino; L J Picker
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

5.  Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA.

Authors:  N Oyaizu; N Chirmule; V S Kalyanaraman; W W Hall; R Pahwa; M Shuster; S Pahwa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

6.  Differential expression of interleukin-2 and gamma interferon in human immunodeficiency virus disease.

Authors:  S F Sieg; D A Bazdar; C V Harding; M M Lederman
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Authors:  Allan R Tenorio; Hongyu Jiang; Yu Zheng; Barbara Bastow; Daniel R Kuritzkes; John A Bartlett; Steven G Deeks; Alan L Landay; Sharon A Riddler
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

8.  Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.

Authors:  Nichole Cerutti; Mark Killick; Vinesh Jugnarain; Maria Papathanasopoulos; Alexio Capovilla
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

9.  Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors.

Authors:  O K Haffar; M D Smithgall; J Bradshaw; B Brady; N K Damle; P S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

Review 10.  Chemokine coreceptor signaling in HIV-1 infection and pathogenesis.

Authors:  Yuntao Wu; Alyson Yoder
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.